{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T20:28:26Z","timestamp":1786739306469,"version":"build-2736575974"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"DOI":"10.4103\/jcrt.jcrt_101_20","type":"journal-article","created":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T08:57:20Z","timestamp":1590569840000},"page":"327-334","source":"Crossref","is-referenced-by-count":18,"title":["Transarterial chemoembolization, ablation, tyrosine kinase inhibitors, and immunotherapy (TATI)"],"prefix":"10.4103","volume":"16","author":[{"given":"Min","family":"Meng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanghui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20-20230619","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1007\/s10620-013-2872-x","article-title":"Combination trans arterial chemoembolization (TACE) plus sorafenib for the management of unresectable hepatocellular carcinoma: A systematic review of the literature","volume":"58","author":"Rahman","year":"2013","journal-title":"Dig Dis Sci"},{"key":"R2-20-20230619","doi-asserted-by":"crossref","first-page":"163","DOI":"10.4103\/jcrt.JCRT_709_16","article-title":"Medical expenditure for liver cancer in urban China: A 10-year multicenter retrospective survey (2002-2011)","volume":"14","author":"Qiu","year":"2018","journal-title":"J Cancer Res Ther"},{"key":"R3-20-20230619","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma","volume":"69","author":"European Association for the Study of the Liver Electronic Address:","year":"2018","journal-title":"J Hepatol"},{"key":"R4-20-20230619","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/hep.29913","article-title":"Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases","volume":"68","author":"Marrero","year":"2018","journal-title":"Hepatol"},{"key":"R5-20-20230619","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.3390\/ijms20061465","article-title":"Treatment strategies for hepatocellular carcinoma \u2013 A multidisciplinary approach","volume":"20","author":"Lurje","year":"2019","journal-title":"Int J Molecular Sci"},{"key":"R6-20-20230619","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1080\/15384047.2017.1323589","article-title":"Comparison of efficacy between TACE combined with apatinib and TACE alone in the treatment of intermediate and advanced hepatocellular carcinoma: A single-center randomized controlled trial","volume":"18","author":"Lu","year":"2017","journal-title":"Cancer Biol Ther"},{"key":"R7-20-20230619","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.4254\/wjh.v7.i8.1054","article-title":"Percutaneous microwave ablation vs radiofrequency ablation in the treatment of hepatocellular carcinoma","volume":"7","author":"Poulou","year":"2015","journal-title":"World J Hepatol"},{"key":"R8-20-20230619","doi-asserted-by":"crossref","first-page":"4614","DOI":"10.3748\/wjg.v25.i32.4614","article-title":"Locoregional treatments for hepatocellular carcinoma: Current evidence and future directions","volume":"25","author":"Inchingolo","year":"2019","journal-title":"World J Gastroenterol"},{"key":"R9-20-20230619","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3109\/00365521.2014.1003397","article-title":"Microwave ablation versus transarterial chemoembolization in large hepatocellular carcinoma: Prospective analysis","volume":"50","author":"Abdelaziz","year":"2015","journal-title":"Scand J Gastroenterol"},{"key":"R10-20-20230619","doi-asserted-by":"crossref","first-page":"766","DOI":"10.4103\/jcrt.JCRT_250_19","article-title":"Percutaneous thermal ablation combined with simultaneous transarterial chemoembolization for hepatocellular carcinoma \u22645 cm","volume":"15","author":"Wu","year":"2019","journal-title":"J Cancer Res Ther"},{"key":"R11-20-20230619","first-page":"305","article-title":"Sorafenib combined with TACE in advanced primary hepatocellular carcinoma","volume":"60","author":"Cui","year":"2013","journal-title":"Hepatogastroenterology"},{"key":"R12-20-20230619","doi-asserted-by":"crossref","first-page":"741","DOI":"10.4103\/jcrt.JCRT_400_19","article-title":"Apatinib for hepatocellular carcinoma","volume":"15","author":"Ni","year":"2019","journal-title":"J Cancer Res Ther"},{"key":"R13-20-20230619","doi-asserted-by":"crossref","first-page":"6075","DOI":"10.2147\/DDDT.S97235","article-title":"Apatinib for molecular targeted therapy in tumor","volume":"9","author":"Zhang","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"R14-20-20230619","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase \u00bd dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"key":"R15-20-20230619","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): A non-randomised, open-label Phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol"},{"key":"R16-20-20230619","doi-asserted-by":"crossref","first-page":"267","DOI":"10.4103\/jcrt.JCRT_910_18","article-title":"Programmed cell death protein-1 inhibitor for the treatment of hepatocellular carcinoma: \u201cA sharp sword\u201d","volume":"15","author":"Li","year":"2019","journal-title":"J Cancer Res Ther"},{"key":"R17-20-20230619","doi-asserted-by":"crossref","first-page":"173","DOI":"10.20892\/j.issn.2095-3941.2018.0172","article-title":"Reactive capillary hemangiomas: A novel dermatologic toxicity following anti-PD-1 treatment with SHR-1210","volume":"16","author":"Chen","year":"2019","journal-title":"Cancer Biol Med"},{"key":"R18-20-20230619","doi-asserted-by":"crossref","first-page":"571","DOI":"10.21147\/j.issn.1000-9604.2018.06.01","article-title":"Liver cancer incidence and mortality in China: Temporal trends and projections to 2030","volume":"30","author":"Zheng","year":"2018","journal-title":"Chin J Cancer Res"},{"key":"R19-20-20230619","doi-asserted-by":"crossref","first-page":"337","DOI":"10.21037\/jgo.2016.09.06","article-title":"Operative microwave ablation for hepatocellular carcinoma: A single center retrospective review of 219 patients","volume":"8","author":"Baker","year":"2017","journal-title":"J Gastrointest Oncol"},{"key":"R20-20-20230619","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1007\/s00270-017-1736-8","article-title":"Transarterial chemoembolization monotherapy versus combined transarterial chemoembolization \u2013 Microwave ablation therapy for hepatocellular carcinoma tumors\u22645 cm: A propensity analysis at a single center","volume":"40","author":"Chen","year":"2017","journal-title":"Cardiovasc Interven Radiol"},{"key":"R21-20-20230619","first-page":"219","article-title":"Combined transarterial chemoembolization and microwave ablation versus transarterial chemoembolization in BCLC stage B hepatocellular carcinoma","volume":"24","author":"Zhang","year":"2018","journal-title":"Diagn Interv Radiol"},{"key":"R22-20-20230619","doi-asserted-by":"crossref","first-page":"727","DOI":"10.4103\/jcrt.JCRT_222_18","article-title":"Angiogenesis and apatinib: Can be used for the patients with non-gastic cancer?","volume":"14","author":"Ni","year":"2018","journal-title":"J Cancer Res Ther"},{"key":"R23-20-20230619","doi-asserted-by":"crossref","first-page":"17220","DOI":"10.18632\/oncotarget.7948","article-title":"Apatinib inhibits VEGF signaling and promotes apoptosis in intrahepatic cholangiocarcinoma","volume":"7","author":"Peng","year":"2016","journal-title":"Oncotarget"},{"key":"R24-20-20230619","doi-asserted-by":"crossref","first-page":"651","DOI":"10.2217\/imt-2018-0214","article-title":"Efficacy and safety of nivolumab plus apatinib in advanced liver carcinosarcoma: A case report","volume":"11","author":"Zhao","year":"2019","journal-title":"Immunother"},{"key":"R25-20-20230619","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.1200\/jco.2014.32.15_suppl.4019","article-title":"Apatinib in Chinese patients with advanced hepatocellular carcinoma: A Phase II randomized, open-label trial","volume":"32(15_suppl)","author":"Qin","year":"2014","journal-title":"Journal of Clinical Oncology"},{"key":"R26-20-20230619","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1158\/1078-0432.CCR-08-1608","article-title":"Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma","volume":"15","author":"Gao","year":"2009","journal-title":"Clin Cancer Res"},{"key":"R27-20-20230619","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1158\/1078-0432.CCR-17-0289","article-title":"Immunotherapy of hepatocellular carcinoma: Facts and hopes","volume":"24","author":"I\u00f1arrairaegui","year":"2018","journal-title":"Clin Cancer Res"},{"key":"R28-20-20230619","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jhep.2016.10.029","article-title":"Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma","volume":"66","author":"Duffy","year":"2017","journal-title":"J Hepatol"},{"key":"R29-20-20230619","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jhep.2013.02.022","article-title":"A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C","volume":"59","author":"Sangro","year":"2013","journal-title":"J Hepatol"},{"key":"R30-20-20230619","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1080\/19420862.2018.1550321","article-title":"Anti-PD1 'SHR-1210\u00b4 aberrantly targets pro-angiogenic receptors and this polyspecificity can be ablated by paratope refinement","volume":"11","author":"Finlay","year":"2019","journal-title":"mAbs"},{"key":"R31-20-20230619","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.4103\/jcrt.JCRT_997_19","article-title":"Salvage therapy of reactive capillary hemangiomas: Apatinib alleviates the unique adverse events induced by camrelizumab in non-small cell lung cancer","volume":"15","author":"Li","year":"2019","journal-title":"J Cancer Res Ther"},{"key":"R32-20-20230619","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1158\/1078-0432.CCR-18-2484","article-title":"Anti-PD-1 antibody SHR-1210 combined with apatinib for advanced hepatocellular carcinoma, gastric, or esophagogastric junction cancer: An open-label, dose escalation and expansion study","volume":"25","author":"Xu","year":"2019","journal-title":"Clin Cancer Res"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_101_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:27:46Z","timestamp":1786735666000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_101_20"}},"subtitle":["A novel treatment for patients with advanced hepatocellular carcinoma"],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_101_20","relation":{},"ISSN":["0973-1482"],"issn-type":[{"value":"0973-1482","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]}}}